Publication

Abstract : Psoriasis is a chronic autoimmune inflammatory disease which affects the skin with hyper proliferation of keratinocytes and relapsing episodes of inflammation. Phosphodiesterase 4(PDE4) is a decisive enzyme in the degradation of cAMP and is centrally involved in the cytokine production, angiogenesis and the functional properties of keratinocytes. Apremilast has anti-inflammatory properties used as phosphodiesterase inhibitor in psoriasis therapy but showing side effects like respiratory tract infection. Dimethyl fumarate is found to be the main therapeutic agent in anti-psoriatic therapy but it exhibits adverse effects such as depression and lymphocytopenia. Chemical conjugation of dimethyl fumarate with chitosan by using mercaptopropionic acid through Michael addition reaction (DMC conjugate) will enhance antipsoriatic activity. The protein characterization was done by PROTPARAM and SOPMA method. In this research docking studies, drug likeness and ADMETox have been executed for the analysis of lead moiety – protein interaction. From this analysis, it has been proved that 2QYL protein has more stability and better docking score compared to other proteins. The computational results convey that the DMC conjugate is an influential PDE4 antagonist to that of standard drug apremilast.